“Onco360 is grateful for the opportunity to partner with the Regeneron team and become a specialty pharmacy provider for Lynozyfic,” said Benito Fernandez, Chief Commercial Officer.“We are proud to ...

The FDA issued a Complete Response Letter for Regeneron’s biologics license application for odronextamab, a bispecific antibody targeting CD20 and CD3 for the treatment of relapsed or refractory ...

Still, the 19-year-old student walked away with the event's $100,000 top prize and a breakthrough idea for making lifesaving ...

During a live event, Hans Lee, MD, and participants discussed potential approaches to modifying frontline multiple myeloma ...

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Regeneron (CRL) for the Biologics License Application (BLA) for odronextamab in relapsed/refractory ...

Analysts estimate that Amgen will report an earnings per share (EPS) of $5.26. The announcement from Amgen is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its ...

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate ...

Local pharma stocks were rocky on Friday after President Donald Trump directed major drugmakers to reduce the cost of their ...